C1



wherein

A is selected from the group consisting of $-NR^8{}_2$, $-NHSO_2R^3$, $-OR^5$, $-SR^5$, halo, lower alkyl, $-CON(R^4)_2$, guanidino, amidino, -H, and perhaloalkyl;

E is selected from the group consisting of -H, halo, lower alkylthio, lower perhaloalkyl, lower alkyl, lower alkenyl, lower alkynyl, lower alkoxy, -CN, and $-NR^7{}_2$;

X together with Y forms a cyclic group selected from the group of heterocyclic, and aryl;

R^1 is independently selected from the group consisting of -H, alkyl, aryl, heteroalicyclic where the cyclic moiety contains a carbonate or thiocarbonate, $-C(R^2)_2$-aryl, –alk-aryl, $-C(R^2)_2OC(O)NR^2{}_2$, $-NR^2$-C(O)-R^3, $-C(R^2)_2$-OC (O)R^3, $-C(R^2)_2$-O-C(O)OR^3, $-C(R^2)_2OC(O)SR^3$, –alk-S-C(O)R^3, –alk-S-S-alkylhydroxy, and –alk-S-S-S-alkylhydroxy, or together R^1 and R^1 are –alk-S-S-alk- to form a cyclic group, wherein each "alk" is an independently selected alkylene, or together R^1 and R^1 are



wherein

V and W are independently selected from the group consisting of hydrogen, aryl, substituted aryl, heteroaryl, substituted heteroaryl, 1-alkenyl, 1-alkynyl, and $-R^9$; or

together V and Z are connected via a chain of 3-5 atoms, only one of which can be a heteroatom, to form part of a cyclic group substituted with hydroxy, acyloxy, alkoxycarboxy, or aryloxycarboxy attached to a carbon atom that is three atoms from an oxygen attached to the phosphorus; or

together V and W are connected via a chain of 3 carbon atoms to form part of a cyclic group substituted with hydroxy, acyloxy, alkoxycarboxy, alkylthiocarboxy, hydroxymethyl, or aryloxycarboxy attached to a carbon atom that is three atoms from an oxygen attached to the phosphorus;

C1

Z is selected from the group consisting of $-CH_2OH$, $-CH_2OCOR^3$, $-CH_2OC(O)SR^3$, $-CH_2OCO_2R^3$, $-SR^3$, $-S(O)R^3$, $-CH_2N_3$, $-CH_2NR^2_2$, $-CH_2Ar$, $-CH(Ar)OH$, $-CH(CH=CR^2R^2)OH$, $-CH(C\equiv CR^2)OH$, and $-R^2$;

with the provisos that:

a) V, Z, W are not all -H; and

b) when Z is $-R^2$, then at least one of V and W is not -H or $-R^9$;

R^2 is selected from the group consisting of R^3 and -H;

R^3 is selected from the group consisting of alkyl, aryl, alicyclic, heteroalicyclic, and aralkyl;

R^4 is independently selected from the group consisting of -H, lower alkyl, lower alicyclic, lower heteroalicyclic, lower aralkyl, and lower aryl;

R^5 is selected from the group consisting of lower alkyl, lower aryl, lower aralkyl, lower heteroalicyclic, and lower alicyclic;

R^6 is independently selected from the group consisting of -H, and lower alkyl;

R^7 is independently selected from the group consisting of -H, lower alkyl, lower alicyclic, lower heteroalicyclic, lower aralkyl, lower aryl, and $-C(O)R^{10}$;

R^8 is independently selected from the group consisting of -H, lower alkyl, lower aralkyl, lower aryl, lower alicyclic, $-C(O)R^{10}$, or together said R^8 groups form a bidendate alkylene;

R^9 is selected from the group consisting of alkyl, aralkyl, , heteroalicyclic, and alicyclic;

R^{10} is selected from the group consisting of -H, lower alkyl, $-NH_2$, lower aryl, and lower perhaloalkyl;

R^{11} is selected from the group consisting of alkyl, aryl, -OH, $-NH_2$ and $-OR^3$; and

pharmaceutically acceptable prodrugs and salts thereof.

C2

34. (Twice Amended) A method of treating an animal for diabetes mellitus, comprising administering to said animal a therapeutically effective amount of a compound of formula (I):

C 2



wherein

A is selected from the group consisting of $-NR^8_2$, $-NHSO_2R^3$, $-OR^5$, $-SR^5$, halo, lower alkyl, $-CON(R^4)_2$, guanidino, amidino, -H, and perhaloalkyl;

E is selected from the group consisting of -H, halo, lower alkylthio, lower perhaloalkyl, lower alkyl, lower alkenyl, lower alkynyl, lower alkoxy, -CN, and $-NR^7_2$;

X together with Y forms a cyclic group selected from the group of heterocyclic, and aryl;

R^1 is independently selected from the group consisting of -H, alkyl, aryl, heteroalicyclic where the cyclic moiety contains a carbonate or thiocarbonate, $-C(R^2)_2$-aryl, –alk-aryl, $-C(R^2)_2OC(O)NR^2_2$, $-NR^2$-C(O)-R^3, $-C(R^2)_2$-OC (O)R^3, $-C(R^2)_2$-O-C(O)OR^3, $-C(R^2)_2OC(O)SR^3$, –alk-S-C(O)R^3, –alk-S-S-alkylhydroxy, and –alk-S-S-S-alkylhydroxy, or together R^1 and R^1 are –alk-S-S-alk- to form a cyclic group, wherein each "alk" is an independently selected alkylene, or together R^1 and R^1 are



wherein

V and W are independently selected from the group consisting of hydrogen, aryl, substituted aryl, heteroaryl, substituted heteroaryl, 1-alkenyl, 1-alkynyl, and $-R^9$; or

together V and Z are connected via a chain of 3-5 atoms, only one of which can be a heteroatom, to form part of a cyclic group substituted with hydroxy, acyloxy, alkoxycarboxy, or aryloxycarboxy attached to a carbon atom that is three atoms from an oxygen attached to the phosphorus; or

together V and W are connected via a chain of 3 carbon atoms to form part of a cyclic group substituted with hydroxy, acyloxy, alkoxycarboxy, alkylthiocarboxy, hydroxymethyl, or aryloxycarboxy attached to a carbon atom that is three atoms from an oxygen attached to the phosphorus;

Z is selected from the group consisting of $-CH_2OH$, $-CH_2OCOR^3$, $-CH_2OC(O)SR^3$, $-CH_2OCO_2R^3$, $-SR^3$, $-S(O)R^3$, $-CH_2N_3$, $-CH_2NR^2_2$, $-CH_2Ar$, $-CH(Ar)OH$, $-CH(CH{=}CR^2R^2)OH$, $-CH(C{\equiv}CR^2)OH$, and $-R^2$;

with the provisos that:

a) V, Z, W are not all -H; and

b) when Z is $-R^2$, then at least one of V and W is not -H or $-R^9$;

R^2 is selected from the group consisting of R^3 and -H;

R^3 is selected from the group consisting of alkyl, aryl, alicyclic, heteroalicyclic, and aralkyl;

R^4 is independently selected from the group consisting of -H, lower alkyl, lower alicyclic, lower heteroalicyclic, lower aralkyl, and lower aryl;

R^5 is selected from the group consisting of lower alkyl, lower aryl, lower aralkyl, lower heteroalicyclic, and lower alicyclic;

R^6 is independently selected from the group consisting of -H, and lower alkyl;

R^7 is independently selected from the group consisting of -H, lower alkyl, lower alicyclic, lower heteroalicyclic, lower aralkyl, lower aryl, and $-C(O)R^{10}$;

R^8 is independently selected from the group consisting of -H, lower alkyl, lower aralkyl, lower aryl, lower alicyclic, $-C(O)R^{10}$, or together said R^8 groups form a bidendate alkylene;

R^9 is selected from the group consisting of alkyl, aralkyl, , heteroalicyclic, and alicyclic;

R^{10} is selected from the group consisting of -H, lower alkyl, $-NH_2$, lower aryl, and lower perhaloalkyl;

R^{11} is selected from the group consisting of alkyl, aryl, -OH, $-NH_2$ and $-OR^3$; and

pharmaceutically acceptable prodrugs and salts thereof.

35. (Twice Amended) A method of lowering blood glucose levels in an animal in need thereof, comprising administering to said animal a pharmaceutically acceptable amount of a compound of formula (1):

C 2



wherein

A is selected from the group consisting of $-NR^8_2$, $-NHSO_2R^3$, $-OR^5$, $-SR^5$, halo, lower alkyl, $-CON(R^4)_2$, guanidino, amidino, -H, and perhaloalkyl;

E is selected from the group consisting of -H, halo, lower alkylthio, lower perhaloalkyl, lower alkyl, lower alkenyl, lower alkynyl, lower alkoxy, -CN, and $-NR^7_2$;

X together with Y forms a cyclic group selected from the group of heterocyclic, and aryl;

R^1 is independently selected from the group consisting of -H, alkyl, aryl, heteroalicyclic where the cyclic moiety contains a carbonate or thiocarbonate, $-C(R^2)_2$-aryl, –alk-aryl, $-C(R^2)_2OC(O)NR^2_2$, $-NR^2-C(O)-R^3$, $-C(R^2)_2-OC(O)R^3$, $-C(R^2)_2-O-C(O)OR^3$, $-C(R^2)_2OC(O)SR^3$, –alk-S-C(O)R^3, –alk-S-S-alkylhydroxy, and –alk-S-S-S-alkylhydroxy, or together R^1 and R^1 are –alk-S-S-alk- to form a cyclic group, wherein each "alk" is an independently selected alkylene, or together R^1 and R^1 are



wherein

V and W are independently selected from the group consisting of hydrogen, aryl, substituted aryl, heteroaryl, substituted heteroaryl, 1-alkenyl, 1-alkynyl, and $-R^9$; or

together V and Z are connected via a chain of 3-5 atoms, only one of which can be a heteroatom, to form part of a cyclic group substituted with hydroxy, acyloxy, alkoxycarboxy, or aryloxycarboxy attached to a carbon atom that is three atoms from an oxygen attached to the phosphorus; or

together V and W are connected via a chain of 3 carbon atoms to form part of a cyclic group substituted with hydroxy, acyloxy, alkoxycarboxy, alkylthiocarboxy, hydroxymethyl, or aryloxycarboxy attached to a carbon atom that is three atoms from an oxygen attached to the phosphorus;

Z is selected from the group consisting of $-CH_2OH$, $-CH_2OCOR^3$, $-CH_2OC(O)SR^3$, $-CH_2OCO_2R^3$, $-SR^3$, $-S(O)R^3$, $-CH_2N_3$, $-CH_2NR^2_2$, $-CH_2Ar$, $-CH(Ar)OH$, $-CH(CH=CR^2R^2)OH$, $-CH(C\equiv CR^2)OH$, and $-R^2$;

C2

with the provisos that:

a) V, Z, W are not all -H; and

b) when Z is $-R^2$, then at least one of V and W is not -H or $-R^9$;

R^2 is selected from the group consisting of R^3 and -H;

R^3 is selected from the group consisting of alkyl, aryl, alicyclic, heteroalicyclic, and aralkyl;

R^4 is independently selected from the group consisting of -H, lower alkyl, lower alicyclic, lower heteroalicyclic, lower aralkyl, and lower aryl;

R^5 is selected from the group consisting of lower alkyl, lower aryl, lower aralkyl, lower heteroalicyclic, and lower alicyclic;

R^6 is independently selected from the group consisting of -H, and lower alkyl;

R^7 is independently selected from the group consisting of -H, lower alkyl, lower alicyclic, lower heteroalicyclic, lower aralkyl, lower aryl, and $-C(O)R^{10}$;

R^8 is independently selected from the group consisting of -H, lower alkyl, lower aralkyl, lower aryl, lower alicyclic, $-C(O)R^{10}$, or together said R^8 groups form a bidendate alkylene;

R^9 is selected from the group consisting of alkyl, aralkyl, , heteroalicyclic, and alicyclic;

R^{10} is selected from the group consisting of -H, lower alkyl, $-NH_2$, lower aryl, and lower perhaloalkyl;

R^{11} is selected from the group consisting of alkyl, aryl, -OH, $-NH_2$ and $-OR^3$; and

pharmaceutically acceptable prodrugs and salts thereof.

36. (Twice Amended) A method of inhibiting FBPase at the AMP site in patients in need thereof, comprising administering to said patients an FBPase inhibitory amount of a compound of formula (1):

C2



wherein

A is selected from the group consisting of $-NR^8_2$, $-NHSO_2R^3$, $-OR^5$, $-SR^5$, halo, lower alkyl, $-CON(R^4)_2$, guanidino, amidino, -H, and perhaloalkyl;

E is selected from the group consisting of -H, halo, lower alkylthio, lower perhaloalkyl, lower alkyl, lower alkenyl, lower alkynyl, lower alkoxy, -CN, and $-NR^7_2$;

X together with Y forms a cyclic group selected from the group of heterocyclic, and aryl;

R^1 is independently selected from the group consisting of -H, alkyl, aryl, heteroalicyclic where the cyclic moiety contains a carbonate or thiocarbonate, $-C(R^2)_2$-aryl, –alk-aryl, $-C(R^2)_2OC(O)NR^2_2$, $-NR^2-C(O)-R^3$, $-C(R^2)_2-OC(O)R^3$, $-C(R^2)_2-O-C(O)OR^3$, $-C(R^2)_2OC(O)SR^3$, –alk-S-C(O)R^3, –alk-S-S-alkylhydroxy, and –alk-S-S-S-alkylhydroxy, or together R^1 and R^1 are –alk-S-S-alk- to form a cyclic group, wherein each "alk" is an independently selected alkylene, or together R^1 and R^1 are



wherein

V and W are independently selected from the group consisting of hydrogen, aryl, substituted aryl, heteroaryl, substituted heteroaryl, 1-alkenyl, 1-alkynyl, and $-R^9$; or

together V and Z are connected via a chain of 3-5 atoms, only one of which can be a heteroatom, to form part of a cyclic group substituted with hydroxy, acyloxy, alkoxycarboxy, or aryloxycarboxy attached to a carbon atom that is three atoms from an oxygen attached to the phosphorus; or

together V and W are connected via a chain of 3 carbon atoms to form part of a cyclic group substituted with hydroxy, acyloxy, alkoxycarboxy, alkylthiocarboxy, hydroxymethyl, or aryloxycarboxy attached to a carbon atom that is three atoms from an oxygen attached to the phosphorus;

Z is selected from the group consisting of $-CH_2OH$, $-CH_2OCOR^3$, $-CH_2OC(O)SR^3$, $-CH_2OCO_2R^3$, $-SR^3$, $-S(O)R^3$, $-CH_2N_3$, $-CH_2NR^2_2$, $-CH_2Ar$, $-CH(Ar)OH$, $-CH(CH=CR^2R^2)OH$, $-CH(C\equiv CR^2)OH$, and $-R^2$;

with the provisos that:

a) V, Z, W are not all -H; and

b) when Z is $-R^2$, then at least one of V and W is not -H or $-R^9$;

R^2 is selected from the group consisting of R^3 and -H;

R^3 is selected from the group consisting of alkyl, aryl, alicyclic, heteroalicyclic, and aralkyl;

R^4 is independently selected from the group consisting of -H, lower alkyl, lower alicyclic, lower heteroalicyclic, lower aralkyl, and lower aryl;

R^5 is selected from the group consisting of lower alkyl, lower aryl, lower aralkyl, lower heteroalicyclic, and lower alicyclic;

R^6 is independently selected from the group consisting of -H, and lower alkyl;

R^7 is independently selected from the group consisting of -H, lower alkyl, lower alicyclic, lower heteroalicyclic, lower aralkyl, lower aryl, and $-C(O)R^{10}$;

R^8 is independently selected from the group consisting of -H, lower alkyl, lower aralkyl, lower aryl, lower alicyclic, $-C(O)R^{10}$, or together said R^8 groups form a bidendate alkylene;

R^9 is selected from the group consisting of alkyl, aralkyl, , heteroalicyclic, and alicyclic;

R^{10} is selected from the group consisting of -H, lower alkyl, $-NH_2$, lower aryl, and lower perhaloalkyl;

R^{11} is selected from the group consisting of alkyl, aryl, -OH, $-NH_2$ and $-OR^3$; and

pharmaceutically acceptable prodrugs and salts thereof.

37. (Twice Amended) A method of inhibiting gluconeogenesis in animal in need thereof, comprising administering to said animal an effective amount of a compound of formula (1):

C2



wherein

A is selected from the group consisting of $-NR^8_2$, $-NHSO_2R^3$, $-OR^5$, $-SR^5$, halo, lower alkyl, $-CON(R^4)_2$, guanidino, amidino, -H, and perhaloalkyl;

E is selected from the group consisting of -H, halo, lower alkylthio, lower perhaloalkyl, lower alkyl, lower alkenyl, lower alkynyl, lower alkoxy, -CN, and $-NR^7_2$;

X together with Y forms a cyclic group selected from the group of heterocyclic, and aryl;

R^1 is independently selected from the group consisting of -H, alkyl, aryl, heteroalicyclic where the cyclic moiety contains a carbonate or thiocarbonate, $-C(R^2)_2$-aryl, –alk-aryl, $-C(R^2)_2OC(O)NR^2_2$, $-NR^2$-C(O)-R^3, $-C(R^2)_2$-OC (O)R^3, $-C(R^2)_2$-O-C(O)OR^3, $-C(R^2)_2OC(O)SR^3$, –alk-S-C(O)R^3, –alk-S-S-alkylhydroxy, and –alk-S-S-S-alkylhydroxy, or together R^1 and R^1 are –alk-S-S-alk- to form a cyclic group, wherein each "alk" is an independently selected alkylene, or together R^1 and R^1 are



wherein

V and W are independently selected from the group consisting of hydrogen, aryl, substituted aryl, heteroaryl, substituted heteroaryl, 1-alkenyl, 1-alkynyl, and $-R^9$; or

together V and Z are connected via a chain of 3-5 atoms, only one of which can be a heteroatom, to form part of a cyclic group substituted with hydroxy, acyloxy, alkoxycarboxy, or aryloxycarboxy attached to a carbon atom that is three atoms from an oxygen attached to the phosphorus; or

together V and W are connected via a chain of 3 carbon atoms to form part of a cyclic group substituted with hydroxy, acyloxy, alkoxycarboxy, alkylthiocarboxy, hydroxymethyl, or aryloxycarboxy attached to a carbon atom that is three atoms from an oxygen attached to the phosphorus;

Z is selected from the group consisting of $-CH_2OH$, $-CH_2OCOR^3$, $-CH_2OC(O)SR^3$, $-CH_2OCO_2R^3$, $-SR^3$, $-S(O)R^3$, $-CH_2N_3$, $-CH_2NR^2_2$, $-CH_2Ar$, $-CH(Ar)OH$, $-CH(CH{=}CR^2R^2)OH$, $-CH(C{\equiv}CR^2)OH$, and $-R^2$;

C2

with the provisos that:

a) V, Z, W are not all -H; and

b) when Z is $-R^2$, then at least one of V and W is not -H or $-R^9$;

R^2 is selected from the group consisting of R^3 and -H;

R^3 is selected from the group consisting of alkyl, aryl, alicyclic, heteroalicyclic, and aralkyl;

R^4 is independently selected from the group consisting of -H, lower alkyl, lower alicyclic, lower heteroalicyclic, lower aralkyl, and lower aryl;

R^5 is selected from the group consisting of lower alkyl, lower aryl, lower aralkyl, lower heteroalicyclic, and lower alicyclic;

R^6 is independently selected from the group consisting of -H, and lower alkyl;

R^7 is independently selected from the group consisting of -H, lower alkyl, lower alicyclic, lower heteroalicyclic, lower aralkyl, lower aryl, and $-C(O)R^{10}$;

R^8 is independently selected from the group consisting of -H, lower alkyl, lower aralkyl, lower aryl, lower alicyclic, $-C(O)R^{10}$, or together said R^8 groups form a bidendate alkylene;

R^9 is selected from the group consisting of alkyl, aralkyl, , heteroalicyclic, and alicyclic;

R^{10} is selected from the group consisting of -H, lower alkyl, $-NH_2$, lower aryl, and lower perhaloalkyl;

R^{11} is selected from the group consisting of alkyl, aryl, -OH, $-NH_2$ and $-OR^3$; and

pharmaceutically acceptable prodrugs and salts thereof.

C3

39. (Twice Amended) A method of treating an animal for a disease derived from abnormally elevated insulin levels, comprising administering to said animal a therapeutically

effective amount of a fructose-1,6-bisphosphatase inhibitor wherein said inhibitor is a compound of formula (1):

C3



wherein

A is selected from the group consisting of $-NR^8_2$, $-NHSO_2R^3$, $-OR^5$, $-SR^5$, halo, lower alkyl, $-CON(R^4)_2$, guanidino, amidino, -H, and perhaloalkyl;

E is selected from the group consisting of -H, halo, lower alkylthio, lower perhaloalkyl, lower alkyl, lower alkenyl, lower alkynyl, lower alkoxy, -CN, and $-NR^7_2$;

X together with Y forms a cyclic group selected from the group of heterocyclic, and aryl;

R^1 is independently selected from the group consisting of -H, alkyl, aryl, heteroalicyclic where the cyclic moiety contains a carbonate or thiocarbonate, $-C(R^2)_2$-aryl, –alk-aryl, $-C(R^2)_2OC(O)NR^2_2$, $-NR^2-C(O)-R^3$, $-C(R^2)_2-OC(O)R^3$, $-C(R^2)_2-O-C(O)OR^3$, $-C(R^2)_2OC(O)SR^3$, –alk-S-C(O)R^3, –alk-S-S-alkylhydroxy, and –alk-S-S-S-alkylhydroxy, or together R^1 and R^1 are –alk-S-S-alk- to form a cyclic group, wherein each "alk" is an independently selected alkylene, or together R^1 and R^1 are



wherein

V and W are independently selected from the group consisting of hydrogen, aryl, substituted aryl, heteroaryl, substituted heteroaryl, 1-alkenyl, 1-alkynyl, and $-R^9$; or

together V and Z are connected via a chain of 3-5 atoms, only one of which can be a heteroatom, to form part of a cyclic group substituted with hydroxy, acyloxy, alkoxycarboxy, or aryloxycarboxy attached to a carbon atom that is three atoms from an oxygen attached to the phosphorus; or

together V and W are connected via a chain of 3 carbon atoms to form part of a cyclic group substituted with hydroxy, acyloxy, alkoxycarboxy, alkylthiocarboxy,

hydroxymethyl, or aryloxycarboxy attached to a carbon atom that is three atoms from an oxygen attached to the phosphorus;

C3

Z is selected from the group consisting of $-CH_2OH$, $-CH_2OCOR^3$, $-CH_2OC(O)SR^3$, $-CH_2OCO_2R^3$, $-SR^3$, $-S(O)R^3$, $-CH_2N_3$, $-CH_2NR^2_2$, $-CH_2Ar$, $-CH(Ar)OH$, $-CH(CH{=}CR^2R^2)OH$, $-CH(C{\equiv}CR^2)OH$, and $-R^2$;

with the provisos that:

a) V, Z, W are not all -H; and

b) when Z is $-R^2$, then at least one of V and W is not -H or $-R^9$;

R^2 is selected from the group consisting of R^3 and -H;

R^3 is selected from the group consisting of alkyl, aryl, alicyclic, heteroalicyclic, and aralkyl;

R^4 is independently selected from the group consisting of -H, lower alkyl, lower alicyclic, lower heteroalicyclic, lower aralkyl, and lower aryl;

R^5 is selected from the group consisting of lower alkyl, lower aryl, lower aralkyl, lower heteroalicyclic, and lower alicyclic;

R^6 is independently selected from the group consisting of -H, and lower alkyl;

R^7 is independently selected from the group consisting of -H, lower alkyl, lower alicyclic, lower heteroalicyclic, lower aralkyl, lower aryl, and $-C(O)R^{10}$;

R^8 is independently selected from the group consisting of -H, lower alkyl, lower aralkyl, lower aryl, lower alicyclic, $-C(O)R^{10}$, or together said R^8 groups form a bidendate alkylene;

R^9 is selected from the group consisting of alkyl, aralkyl, , heteroalicyclic, and alicyclic;

R^{10} is selected from the group consisting of -H, lower alkyl, $-NH_2$, lower aryl, and lower perhaloalkyl;

R^{11} is selected from the group consisting of alkyl, aryl, -OH, $-NH_2$ and $-OR^3$; and

pharmaceutically acceptable prodrugs and salts thereof.

C4

42. (Twice Amended) A method of treating an animal with excess glycogen storage disease, comprising administering to said animal in need thereof a therapeutically

effective amount of a fructose-1,6-bisphosphatase inhibitor, wherein said inhibitor is a compound of formula (1):



wherein

A is selected from the group consisting of $-NR^8_2$, $-NHSO_2R^3$, $-OR^5$, $-SR^5$, halo, lower alkyl, $-CON(R^4)_2$, guanidino, amidino, -H, and perhaloalkyl;

E is selected from the group consisting of -H, halo, lower alkylthio, lower perhaloalkyl, lower alkyl, lower alkenyl, lower alkynyl, lower alkoxy, -CN, and $-NR^7_2$;

X together with Y forms a cyclic group selected from the group of heterocyclic, and aryl;

R^1 is independently selected from the group consisting of -H, alkyl, aryl, heteroalicyclic where the cyclic moiety contains a carbonate or thiocarbonate, $-C(R^2)_2$-aryl, –alk-aryl, $-C(R^2)_2OC(O)NR^2_2$, $-NR^2$-C(O)-R^3, $-C(R^2)_2$-OC (O)R^3, $-C(R^2)_2$-O-C(O)OR^3, $-C(R^2)_2OC(O)SR^3$, –alk-S-C(O)R^3, –alk-S-S-alkylhydroxy, and –alk-S-S-S-alkylhydroxy, or together R^1 and R^1 are –alk-S-S-alk- to form a cyclic group, wherein each "alk" is an independently selected alkylene, or together R^1 and R^1 are



wherein

V and W are independently selected from the group consisting of hydrogen, aryl, substituted aryl, heteroaryl, substituted heteroaryl, 1-alkenyl, 1-alkynyl, and $-R^9$; or

together V and Z are connected via a chain of 3-5 atoms, only one of which can be a heteroatom, to form part of a cyclic group substituted with hydroxy, acyloxy, alkoxycarboxy, or aryloxycarboxy attached to a carbon atom that is three atoms from an oxygen attached to the phosphorus; or

C4

together V and W are connected via a chain of 3 carbon atoms to form part of a cyclic group substituted with hydroxy, acyloxy, alkoxycarboxy, alkylthiocarboxy, hydroxymethyl, or aryloxycarboxy attached to a carbon atom that is three atoms from an oxygen attached to the phosphorus;

Z is selected from the group consisting of $-CH_2OH$, $-CH_2OCOR^3$, $-CH_2OC(O)SR^3$, $-CH_2OCO_2R^3$, $-SR^3$, $-S(O)R^3$, $-CH_2N_3$, $-CH_2NR^2_2$, $-CH_2Ar$, $-CH(Ar)OH$, $-CH(CH{=}CR^2R^2)OH$, $-CH(C{\equiv}CR^2)OH$, and $-R^2$;

with the provisos that:

a) V, Z, W are not all -H; and

b) when Z is $-R^2$, then at least one of V and W is not -H or $-R^9$;

R^2 is selected from the group consisting of R^3 and -H;

R^3 is selected from the group consisting of alkyl, aryl, alicyclic, heteroalicyclic, and aralkyl;

R^4 is independently selected from the group consisting of -H, lower alkyl, lower alicyclic, lower heteroalicyclic, lower aralkyl, and lower aryl;

R^5 is selected from the group consisting of lower alkyl, lower aryl, lower aralkyl, lower heteroalicyclic, and lower alicyclic;

R^6 is independently selected from the group consisting of -H, and lower alkyl;

R^7 is independently selected from the group consisting of -H, lower alkyl, lower alicyclic, lower heteroalicyclic, lower aralkyl, lower aryl, and $-C(O)R^{10}$;

R^8 is independently selected from the group consisting of -H, lower alkyl, lower aralkyl, lower aryl, lower alicyclic, $-C(O)R^{10}$, or together said R^8 groups form a bidendate alkylene;

R^9 is selected from the group consisting of alkyl, aralkyl, , heteroalicyclic, and alicyclic;

R^{10} is selected from the group consisting of -H, lower alkyl, $-NH_2$, lower aryl, and lower perhaloalkyl;

R^{11} is selected from the group consisting of alkyl, aryl, -OH, $-NH_2$ and $-OR^3$; and

pharmaceutically acceptable prodrugs and salts thereof.